Medium materiality6/10
Canaccord Raises CareDx Price Target to $99
Why it may matterVerify against the original reporting
The target increase and stated revenue-growth view are positive, though this remains a single analyst opinion.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Canaccord raised its target on CDNA to $99 from an unspecified prior target; the posted price was $71.52, implying roughly 38% upside to the new target.
- Target raised to $99; posted price $71.52.
- Canaccord cited its view that CDNA is positioned for solid revenue expansion over time.
Key facts
- 01
Target: $99
- 02
Posted price: $71.52
- 03
Analyst firm: Canaccord Genuity
- 04
Analyst: Kyle Mikson
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.